Back to Search
Start Over
Surviving with lung cancer: Medication-taking and oral targeted therapy
- Source :
- Geriatric Nursing. 35:S49-S56
- Publication Year :
- 2014
- Publisher :
- Elsevier BV, 2014.
-
Abstract
- Oral epidermal growth factor receptor inhibitors (EGFRIs) improve survival for non-small cell lung cancer (NSCLC) patients; however, medication-taking implications are unknown. We used grounded theory to explore the process of medication-taking for NSCLC patients receiving oral EGFRIs. Thirty-two interviews were conducted for 13 participants purposively selected for gender, race/ethnicity, age, time in therapy, dose reductions, and therapy discontinuation and theoretically sampled for age and health insurance carrier. The study produced a grounded theory, Surviving with Lung Cancer, in which participants framed EGFRI therapy within recognition of NSCLC as a life-limiting illness without cure. Medication-taking was a “window” into participants' process of surviving with metastatic cancer that included deciding and preparing to take EGFRIs and treating lung cancer as a chronic condition. Our results contribute to understanding how NSCLC patients view themselves in the context of a life-limiting illness and support development of a theoretically-based intervention to improve medication-taking with EGFRIs.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Chronic condition
Lung Neoplasms
medicine.medical_treatment
Administration, Oral
Antineoplastic Agents
Context (language use)
Article
Targeted therapy
Internal medicine
medicine
Humans
Epidermal growth factor receptor
Lung cancer
biology
business.industry
Cancer
medicine.disease
respiratory tract diseases
Discontinuation
biology.protein
Patient Compliance
Female
Erlotinib
business
Gerontology
medicine.drug
Subjects
Details
- ISSN :
- 01974572
- Volume :
- 35
- Database :
- OpenAIRE
- Journal :
- Geriatric Nursing
- Accession number :
- edsair.doi.dedup.....a3c9849815247a4144b5be02ce48d07b